TAG:
JNCCN
Payers Continue to Increase Coverage of Liquid Biopsies
SINCE THE FIRST BLOOD-BASED, circulating-tumor DNA (ctDNA) sequencing test for cancer became available in 2014, federal and private payer coverage of these so-called “liquid biopsy” tests has increased substantially. Now, clinical laboratory and pathology directors can expect additional coverage …
CURRENT ISSUE
Volume XXIX, No. 7 – May 16, 2022
Better collection and use of clinical data was a prominent theme discussed by attendees at last month’s annual Executive War College Conference on Laboratory and Pathology Management in New Orleans. Also, an attorney warns that federal fraud investigators are targeting labs that did extensive COVID-19 testing during the height of the pandemic.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.